Madopar HBS

Madopar HBS is a sustained-release oral formulation of the combination therapy levodopa and benserazide, specifically designed using a Hydrodynamically Balanced System (HBS). This technology involves a capsule that remains buoyant on the gastric contents, allowing for the slow and continuous release of active ingredients into the stomach and proximal small intestine, which helps maintain more stable plasma levels of levodopa. Levodopa is a metabolic precursor to dopamine that crosses the blood-brain barrier to compensate for dopamine deficiency in the striatum of patients with Parkinson's disease. Benserazide is a peripheral aromatic L-amino acid decarboxylase inhibitor that prevents the premature conversion of levodopa into dopamine outside the central nervous system, thereby increasing the amount of levodopa available to the brain and minimizing peripheral side effects such as nausea and cardiovascular fluctuations. Madopar HBS is primarily indicated for patients with advanced Parkinson's disease who experience motor fluctuations like 'on-off' phenomena or nocturnal immobility.

Brand names

Madopar HBSMadopar CRProlopa HBS

Other names

levodopa + benserazide sustained releaselevodopa + benserazide HBS